ArticleLancet (London, England)2013
Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).
Article in Lancet (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Interventions for basal cell carcinoma of the skin.The Cochrane database of systematic reviews · 2020Pooled it
- A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.Respiratory research · 2018Trial
- The 10-23 DNAzyme in Biosensing and Diagnostics: Applications, Challenges, and Future Directions.Angewandte Chemie (International ed. in English) · 2026Review
- A Modular DNAzyme for Precise Visualization and Intervention of Alternative Splicing Isoforms in Live Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- DNAzyme targeting RIP3 suppresses NLRP3-mediated necroinflammation for the treatment of inflammatory diseases.Acta pharmaceutica Sinica. B · 2025Article
- The coming of age of DNA-based catalysts for therapeutic applications.Clinical and translational medicine · 2025Article
- Facilitating DNAzyme transport across the blood-brain barrier with nanoliposome technology.Scientific reports · 2025Article
- Influence of LNA modifications on the activity of the 10-23 DNAzyme.RSC advances · 2025Article
- Jun, an Oncological Foe or Friend?International journal of molecular sciences · 2025Review
- Single-stranded DNA oligonucleotides containing CpG motifs are non-stimulatoryFrontiers in cellular and infection microbiology · 2024Article
- Development of 8-17 XNAzymes that are functional in cells.Chemical science · 2023Article
- DNAzymes: Expanding the Potential of Nucleic Acid Therapeutics.Nucleic acid therapeutics · 2023Review
- Chemical evolution of an autonomous DNAzyme with allele-specific gene silencing activity.Nature communications · 2023Article
- A computational approach to identify efficient RNA cleaving 10-23 DNAzymes.NAR genomics and bioinformatics · 2023Article
- A promising nucleic acid therapy drug: DNAzymes and its delivery system.Frontiers in molecular biosciences · 2023Review
- Nucleic Acids as Novel Therapeutic Modalities to Address Multiple Sclerosis Onset and Progression.Cellular and molecular neurobiology · 2022Review
- DNAzyme as a rising gene-silencing agent in theranostic settings.Neural regeneration research · 2022Article
- Specificity of oligonucleotide gene therapy (OGT) agents.Theranostics · 2022Review
- Solution NMR Spectroscopy as a Tool to Study DNAzyme Structure and Function.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Review
Corrections and comments
- Commented on by
Authors and funding
18 authors at 8 institutions in 4 countries.
Funding
Abstract
backgroundThe nuclear transcription factor c-Jun is preferentially expressed in basal-cell carcinoma. Dz13 is a deoxyribozyme that targets JUN messenger RNA and has inhibited the growth of a range of tumours in mice. We did a phase 1 study to assess safety and tolerability in human beings.
methodsAdults with nodular basal-cell carcinoma were recruited from Royal Prince Alfred Hospital, Sydney, Australia, between September, 2010, and October, 2011. Patients were assigned to receive one intratumoral injected dose of 10, 30, or 100 μg Dz13, in a 50 μL volume of lipid carrier, and were assessed for adverse effects in the first 24 h then at 7, 14, and 28 days after injection. Treated tumours were surgically excised 14 days after injection and compared with the baseline biopsy samples for expression of c-Jun and tumorigenesis markers.
findingsNine patients were recruited, of whom three received each dose of Dz13. All patients completed the study with no drug-related serious adverse events. No systemic Dz13 exposure was detected. c-Jun expression was reduced in the excised tumours of all nine (100%) patients, compared with baseline, and histological tumour depth had decreased in five (56%) of nine. Proportions of cells positive for caspases 3, 8, and 9 and P53 were increased, but those of cells positive for Bcl-2 and MMP-9 were decreased. Infiltration by inflammatory and immune cells was stimulated.
interpretationDz13 was safe and well tolerated after single intratumoral injections at all doses.
fundingCancer Institute NSW, Cancer Council Australia, and National Health and Medical Research Council.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.